CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - UNAUDITED - USD ($)
$ in Thousands |
Total |
Common Stock |
Additional Paid in Capital |
Accumulated Deficit |
| Balance, beginning of period (in shares) at Dec. 31, 2021 |
|
12,193,378
|
|
|
| Balance, beginning of period at Dec. 31, 2021 |
$ 37,981
|
$ 1
|
$ 60,686
|
$ (22,706)
|
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
| Net (loss) income |
3,964
|
|
|
3,964
|
| Conversion of private warrants to public warrants |
725
|
|
725
|
|
| Tax paid on behalf of employees related to net settlement of share-based awards (in shares) |
|
(37,506)
|
|
|
| Tax paid on behalf of employees related to net settlement of share-based awards |
(225)
|
|
(225)
|
|
| Share-based compensation expense (in shares) |
|
90,075
|
|
|
| Share-based compensation expense |
2,919
|
|
2,919
|
|
| Balance, end of period (in shares) at Mar. 31, 2022 |
|
12,245,947
|
|
|
| Balance, end of period at Mar. 31, 2022 |
45,364
|
$ 1
|
64,105
|
(18,742)
|
| Balance, beginning of period (in shares) at Dec. 31, 2021 |
|
12,193,378
|
|
|
| Balance, beginning of period at Dec. 31, 2021 |
37,981
|
$ 1
|
60,686
|
(22,706)
|
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
| Net (loss) income |
8,326
|
|
|
|
| Balance, end of period (in shares) at Jun. 30, 2022 |
|
12,238,947
|
|
|
| Balance, end of period at Jun. 30, 2022 |
52,779
|
$ 1
|
67,158
|
(14,380)
|
| Balance, beginning of period (in shares) at Mar. 31, 2022 |
|
12,245,947
|
|
|
| Balance, beginning of period at Mar. 31, 2022 |
45,364
|
$ 1
|
64,105
|
(18,742)
|
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
| Net (loss) income |
4,362
|
|
|
4,362
|
| Share-based compensation expense (in shares) |
|
(7,000)
|
|
|
| Share-based compensation expense |
3,053
|
|
3,053
|
|
| Balance, end of period (in shares) at Jun. 30, 2022 |
|
12,238,947
|
|
|
| Balance, end of period at Jun. 30, 2022 |
$ 52,779
|
$ 1
|
67,158
|
(14,380)
|
| Balance, beginning of period (in shares) at Dec. 31, 2022 |
12,240,237
|
12,240,237
|
|
|
| Balance, beginning of period at Dec. 31, 2022 |
$ 48,858
|
$ 1
|
72,342
|
(23,485)
|
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
| Net (loss) income |
(4,960)
|
|
|
(4,960)
|
| Conversion of private warrants to public warrants |
20
|
|
20
|
|
| Tax paid on behalf of employees related to net settlement of share-based awards (in shares) |
|
(473,874)
|
|
|
| Tax paid on behalf of employees related to net settlement of share-based awards |
(2,429)
|
|
(2,429)
|
|
| Share-based compensation expense (in shares) |
|
95,147
|
|
|
| Share-based compensation expense |
447
|
|
447
|
|
| Balance, end of period (in shares) at Mar. 31, 2023 |
|
11,861,510
|
|
|
| Balance, end of period at Mar. 31, 2023 |
$ 41,936
|
$ 1
|
70,380
|
(28,445)
|
| Balance, beginning of period (in shares) at Dec. 31, 2022 |
12,240,237
|
12,240,237
|
|
|
| Balance, beginning of period at Dec. 31, 2022 |
$ 48,858
|
$ 1
|
72,342
|
(23,485)
|
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
| Net (loss) income |
$ (9,416)
|
|
|
|
| Balance, end of period (in shares) at Jun. 30, 2023 |
11,866,345
|
11,866,345
|
|
|
| Balance, end of period at Jun. 30, 2023 |
$ 38,043
|
$ 1
|
70,943
|
(32,901)
|
| Balance, beginning of period (in shares) at Mar. 31, 2023 |
|
11,861,510
|
|
|
| Balance, beginning of period at Mar. 31, 2023 |
41,936
|
$ 1
|
70,380
|
(28,445)
|
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
| Net (loss) income |
(4,456)
|
|
|
(4,456)
|
| Tax paid on behalf of employees related to net settlement of share-based awards (in shares) |
|
(1,765)
|
|
|
| Tax paid on behalf of employees related to net settlement of share-based awards |
(5)
|
|
(5)
|
|
| Share-based compensation expense (in shares) |
|
6,600
|
|
|
| Share-based compensation expense |
$ 568
|
|
568
|
|
| Balance, end of period (in shares) at Jun. 30, 2023 |
11,866,345
|
11,866,345
|
|
|
| Balance, end of period at Jun. 30, 2023 |
$ 38,043
|
$ 1
|
$ 70,943
|
$ (32,901)
|